Effect of Empagliflozin on Quality of Life in Chronic Heart Failure Patients With Diabetes Mellitus Type II
Recruiting · NCT06706791 · Interventional (participants receive a specific treatment) · Lead sponsor: Fazaia Ruth Pfau Medical College
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Effect of Empagliflozin on Quality of Life in patient of Chronic Heart Failure with Diabetes Mellitus Type II. As per ESC Guidelines Empagliflozin is recommended as part of the first-line treatment for HFrEF, irrespective of diabetes status. As per American College of Cardiology (ACC)/American Heart Association (AHA) Empagliflozin is recommended in both diabetic and non-diabetic HF (especially beneficial in patients with HFrEF and HFpEF). The aim of my study is to assess the impact of Empagliflozin on quality of life in Pakistani patients, considering the genetic, environmental and cultural factors. The study will also explore whether Empagliflozin can offer cost-effective option for managing chronic heart failure and diabetes, potentially reducing the economic burden on both patients and health care system.
Who can take part
Inclusion criteria
- Age 40-70 years at time of screening.
- Both Men and women are included in study.
- Patients with chronic heart failure and currently categorized in class II-IV heart failure as per NHYA classification having ejection fraction less than 40%.
- Patients having NT- proBNP levels greater than 25pg/ml.
- Diabetic patient diagnosed (HbA1c \> 6.5mg/dl) and currently taking antidiabetic medicine.
Exclusion criteria
- Pregnant female.
- Patient with end stage renal disease (ESRD).
- Patient with acute decompensated heart failure.
- Acute coronary syndrome patients.
Where it is running
1 location listed.
- Fazaia Ruth Pfau Hospital - Karachi, Sindh, Pakistan